For the year ending 2025-12-31, ELVN had -$25,275K decrease in cash & cash equivalents over the period. -$70,459K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -103,694 |
| Depreciation | 263 |
| Stock-based compensation | 34,019 |
| Non-cash lease expense | 353 |
| Amortization of premiums and discounts on marketable securities, net | 227 |
| Change in fair value of contingent value right liability | 0 |
| Loss on disposal of property and equipment | -106 |
| Prepaid expenses, other current and long-term assets | 1,105 |
| Operating lease liabilities | -337 |
| Accounts payable | 817 |
| Accrued expenses and other liabilities | -496 |
| Net cash used in operating activities | -70,301 |
| Maturities of marketable securities | 272,898 |
| Purchases of marketable securities | 446,794 |
| Receipt of contingent value right milestone | 0 |
| Payment of contingent value right milestone, net of permitted deductions | 0 |
| Purchases of property and equipment | 158 |
| Proceeds from sale of property and equipment | 213 |
| Net cash used in investing activities | -173,841 |
| Proceeds from exercise of stock options | 2,295 |
| Proceeds from issuance of common stock under the employee stock purchase plan | 620 |
| Proceeds from issuance of common stock and pre-funded warrants in the public offering, net of issuance costs | 216,169 |
| Proceeds from issuance of common stock and pre-funded warrants in the private placement, net of issuance costs | 0 |
| Proceeds from issuance of common stock under the sales agreement, net of issuance costs | 0 |
| Payment of deferred offering costs | 217 |
| Net cash provided by financing activities | 218,867 |
| Net (decrease) increase in cash, cash equivalents and restricted cash | -25,275 |
| Cash, cash equivalents and restricted cash at the beginning of the period | 124,171 |
| Cash, cash equivalents and restricted cash at the end of the period | 98,896 |
Enliven Therapeutics, Inc. (ELVN)
Enliven Therapeutics, Inc. (ELVN)